文章预览
The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is cooperating with authorities, though details of the investigation are unclear. Two days after AstraZeneca announced that Wang Lei, head of its China operations, is under investigation, questions are growing over the company’s role within China’s health care sector. The British-Swedish pharmaceutical company confirmed that Wang, also AstraZeneca’s executive vice president, is cooperating with authorities, though specifics of the investigation remain unclear. The case emerges amid China’s heightened efforts to address irregularities in its health care sector. While shares of AstraZeneca fell more than 4% on the NASDAQ exchange Wednesday, the company announced that its operations in China would continue under the current general manager’s leadership, adding that it would fully cooperate with authorities if needed. Lin Jian, a spokesperson for China’s
………………………………
